For example, the FLOW trial demonstrated that GLP-1 medications can slow CKD progression and lower the risk of kidney failure
"I'm connected on social media, but I didnt share my weight-loss journey because I didn't want to be judged
Follow Eli Lilly's investor relations page for press releases
Nauck and the other, anonymous reviewer(s) for their contribution to the peer review of this work
Eur J Endocrinol 191(6):G1G17 [DOI] [PubMed] [Google Scholar] 61.Mansur SA, Mieczkowska A, Bouvard B, Flatt PR, Chappard D, Irwin N, Mabilleau G (2015) Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus
This tachyphylaxis occurs with continuous infusion of GLP-1 (154, 157), long acting GLP-1RAs (156), or tirzepatide (151)